AnalystsGavin Clark-GartnerGavin Clark-Gartner's Stock Forecasts
AnalystsGavin Clark-Gartner
Sectors:
Analyst Ranking
Bottom 6%
#4993 out of 5296 analysts
Average Return
-5.69%
Win Rate
44%22 out of 50
Risk vs Reward
Poor
Good
Gavin Clark-Gartner's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Definium Therapeutics IncDFTX | +135.26% | $7.43 | $17.48 | 2025-01-28 - 2026-01-27 | Buy |
Argenx SeARGX | +76.16% | $354.13 | $623.82 | 2023-12-21 - 2024-12-20 | Buy |
Mirum Pharmaceuticals IncMIRM | +68.42% | $59.97 | $101.00 | 2025-08-08 - 2026-06-15 | Buy |
Mirum Pharmaceuticals IncMIRM | +54.43% | $65.40 | $101.00 | 2025-12-09 - 2026-06-15 | Buy |
Argenx SeARGX | +53.92% | $596.74 | $918.50 | 2024-11-21 - 2025-11-20 | Buy |
Gavin Clark-Gartner Analyst Color
Get additional color on Gavin Clark-Gartner's coverage of popular stocks
Gavin Clark-Gartner's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
C4 Therapeutics IncCCCC | 2 | Buy | $12.00 | +214.14% | Maintains | 16 days ago |
Avalyn Pharma IncAVLN | 1 | Buy | $51.00 | +77.39% | Initiates Coverage On | 22 days ago |
Vera Therapeutics IncVERA | 2 | Buy | $91.00 | +165.77% | Maintains | a month ago |
Dyne Therapeutics IncDYN | 2 | Buy | $33.00 | +76.19% | Maintains | a month ago |
Argenx SeARGX | 6 | Buy | $1,059.00 | +19.77% | Maintains | a month ago |
Abbvie IncABBV | 8 | Buy | $235.00 | +6.05% | Maintains | a month ago |
Mirum Pharmaceuticals IncMIRM | 6 | Buy | $138.00 | +36.63% | Maintains | a month ago |
Krystal Biotech IncKRYS | 2 | Buy | $300.00 | -7.62% | Maintains | a month ago |
Meiragtx Holdings PLCMGTX | 1 | Buy | $18.00 | +84.62% | Maintains | 3 months ago |
Jasper Therapeutics IncJSPR | 5 | Buy | $7.00 | +1,358.33% | Maintains | 3 months ago |
Damora Therapeutics IncDMRA | 1 | Buy | $46.00 | +129.20% | Initiates Coverage On | 3 months ago |
Evommune IncEVMN | 1 | Buy | $40.00 | +91.94% | Initiates Coverage On | 7 months ago |
Forte Biosciences IncFBRX | 1 | Buy | $65.00 | +260.11% | Initiates Coverage On | 7 months ago |
Proqr Therapeutics NvPRQR | 1 | Buy | $5.00 | N/A | Initiates Coverage On | a year ago |
Definium Therapeutics IncDFTX | 1 | Buy | $23.00 | N/A | Initiates Coverage On | a year ago |
Cabaletta Bio IncCABA | 2 | Hold | $6.00 | N/A | Downgrades | a year ago |
Sarepta Therapeutics IncSRPT | 9 | Buy | $170.00 | N/A | Maintains | 2 years ago |
Foghorn Therapeutics IncFHTX | 1 | Buy | $20.00 | N/A | Initiates Coverage On | 2 years ago |
Aclaris Therapeutics IncACRS | 1 | Buy | $22.00 | N/A | Initiates Coverage On | 3 years ago |
Inhibrx IncINBX1 | 1 | Buy | $60.00 | N/A | Maintains | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.